With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune ...

Eli Lilly’s CEO, Dave Ricks, has been named the recipient of the 2024 August M. Watanabe Life Sciences Champion of the Year ...

Right now, Eli Lilly dominates the weight loss industry thanks to its ... During the company's earnings call, Viking CEO ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...